Axios Pro Exclusive Content

Ryan Breslow bolts into pharma with $7.5M seed

Illustration of a hundred dollar bill with Benjamin Franklin dressed as a doctor and holding a prescription pill bottle.

Illustration: Victoria Ellis/Axios

Ryan Breslow, the millennial billionaire and founder of buzzy fintech company Bolt, is returning to his entrepreneurial journey with Love.

Why it matters: The startup — named because it aims to crowdsource pharmaceutical R&D — has raised $7.5 million in seed funding at a $180 million valuation.

  • Breslow has also named Kevin Horgan, who once served as GE Healthcare's head of internal medicine diagnostics, Love's chief medical officer.
  • "Instead of focusing on developing a new drug, we’re open minded about what the solutions might be," Horgan tells Axios exclusively. "Could be a natural supplement, a dietary solution, an old drug, a new drug, or combinations of the above."

Deal details: Human Capital and MaC Venture Capital participated in the fundraise.

The backstory: Love is Breslow's first foray into digital health.

  • Asked if he had health care experience, Breslow tells Axios, "No. Did I have a background in fintech before Bolt? No. I just try to be the dumbest person in the room and surround myself with smart people. I think that’s my superpower."

How it (should) work: Love is launching a decentralized autonomous organization (DAO) to gather real world evidence — also known as data — from people's lived experiences.

  • The company plans to include information on people's experiences with what it calls "natural" and homeopathic solutions, generic chemicals and non-substance based treatments such as meditation. (To be clear, the scientific evidence supporting homeopathy is scant.)
  • Its initial focus areas include long COVID, chronic fatigue syndrome, fibromyalgia and substance use disorders, says Horgan.
  • Stacy McIntosh, the former SVP of regulatory affairs for Ridgeback Biotherapeutics, is chief regulatory officer.

Yes, and: Randomized clinical trials are considered the gold standard source of information for drug development, but recent FDA guidance encourages pharma companies to use real-world evidence in addition to RCT data.

  • "Mining real world evidence will be a focal point of our activities," Horgan tells Axios.

The intrigue: Crowdsourcing feedback based on individual experiences with alternative treatments is a tricky endeavor that could result in more anecdotes than data, because unlike drugs, alternative approaches are unregulated.

  • "It seems they’re building out a lane for alternatives, but that’s a tough lane to build in," says Antonio Ciaccia, a pharmacy sector analyst and the CEO of research firm 46brooklyn. "There’s a lot of room for bullsh-- there. It’s kind of the Wild West, and from a consumer perspective, you’re very much left guessing."

What they're saying: Breslow and Horgan aim to assemble a dataset for alternative approaches — including homeopathy — whether that means finding evidence to back it or discount it altogether.

  • "It’s not patentable for Big Pharma, so it’s an area we’d like to provide the data for and put an end to the speculation," says Breslow.
Go deeper